Agenus Inc. · NASDAQ:AGEN
Agenus — FY2019 Earnings Presentation
7 slides from Agenus's earnings presentation, Mar 12, 2020
Slide 1: Earnings Call: 4Q and Full Year 2019 Earnings
Earnings Call: 4Q and Full Year 2019 Earnings March 12, 2020
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding Agenus and AgenTus' clinical development and regulatory plans and timelines, expected timing for clinic
Slide 3: Agenus Pipeline
Mechanism/Target Product Partner Preclinical Phase 1 Phase 2 Phase 3 Filed Approved Fully-owned CTLA-4 Zalifrelimab (AGEN 1884) Pipeline PD-1 Balstilimab (AGEN 2034) Next-generation CTLA-4 AGEN1181 NK cell (bispecific) AGEN1777 Tumor-associated macrophage AGEN1531 TIGIT Cytokine (bispecific) TME con
Slide 4: Balstilimab + Zalifrelimab ORR Increased from ~21% to ~27% with Data Maturity in 2L
Balstilimab + Zalifrelimab ORR Increased from ~21% to ~27% with Data Maturity in 2L Cervical Cancer Early Analysis Mature Analysis (N=34) (N=34) 4.7 mo. Median F/U 12.2 mo. Median F/U Confirmed Overall Response Rate (ORR %) 20.6 26.5 [95% CI] [8.7, 37.9] [14.6, 43.1] Complete Response (%) 8.8 11.8 P
Slide 5: CTLA-4 Improves PD-1 Responses & Durability in Multiple Tumors
CTLA-4 Improves PD-1 Responses & Durability in Multiple Tumors Previously treated MSI-H CRC 34% 58% PD-1 ORR 1L Melanoma 45% 57% PD-1/CTLA-4 ORR 1L NSCLC (≥50% PD-L1) 37% 45% 1L RCC 36% 41% 2L+ Bladder cancer 21% 38% 1L NSCLC (≥1% PD-L1) 28% 36% Ovarian cancer 12% 31% 2L+ Hepatocellular cancer 20% 3
Slide 6: Agenus Notable Strategic Partnerships
Agenus Notable Strategic Partnerships ~$2.5B in potential milestones & royalties; $540M1 already received $172.5M $10M $145M $9M $205M received2 received received3 received received1 Eligible Eligible Eligible Eligible Eligible • $1.7Bn milestones • $200M milestones • $450M milestones • $85M milesto
Slide 7: ogenus
ogenus
Agenus — FY2019 Earnings Presentation on 6ix